1A

Application fee for processing an application for consent under section   14 or 14A of the Act:

(a) for an application relating to goods to which a single entry in the Register relates

565 (for all the goods to which the application relates)

(b) for an application relating to goods to which both of the following apply:

(i) there are separate entries in the Register in relation to the goods;

(ii) the way in which the goods do not conform with a standard applicable to the goods is the same for all the goods

565 for the first entry plus 113 for each additional entry

(c) for an application relating to goods to which no entry in the Register relates

3,712

1

Evaluation fee for the purposes of subparagraph   19(2)(b)(iii) of the Act

(a) if:

(i) the goods are medicines for use solely for experimental purposes in humans; and

(ii) the evaluation consists of the consideration of:

(A) a summary of chemical, pharmaceutical and biological information about the goods; and

(B) descriptive information about the proposed clinical trial of the goods; and

(C) information about adverse events associated with the use of the goods; and

(D) information about the goods provided to the relevant ethics committee;

--for each medicine

2,046

(b) if the goods are medicines for use solely for experimental purposes in humans (other than medicines to which paragraph   (a) applies)--for each medicine

25,426

1AAA

Fee for the purposes of paragraph   19(4B)(e) of the Act, for a request under subsection   19(4B) to vary the therapeutic goods specified in an approval to use those goods solely for experimental purposes in humans, or to vary the conditions of such an approval:

(a) if the request relates to:

(i) goods that are medicines; and

(ii) paragraph   (a) of item   1 applied to the evaluation of the application for approval

562

(b) if the request relates to:

(i) goods that are medicines; and

(ii) paragraph   (b) of item   1 applied to the evaluation of the application for approval

6,940

1AA

Application fee for the purposes of paragraph   22C(2)(b) of the Act for an application under subsection   22C(1) of the Act

14,805

1AB

Application fee for the purposes of paragraph   22E(4)(c) of the Act for an application under subsection   22E(3) of the Act

5,368

1ABA

Fee for the purposes of paragraph   22G(8)(b) of the Act for a request under section   22G of the Act

9,786

1AC

Application fee for the purposes of paragraph   23B(2)(b) of the Act for an application under section   23 of the Act for registration of a medicine in relation to which a provisional determination under section   22D of the Act is in force:

(a) if the application relates to a new prescription medicine

56,956

(b) if the application relates to a new indications medicine

34,016

1AD

Evaluation fee for the purposes of subsection   24(1A) of the Act for an application under section   23 of the Act for registration of a medicine in relation to which a provisional determination under section   22D of the Act is in force:

(a) if the evaluation relates to a new prescription medicine

297,212

(b) if the evaluation relates to a new indications medicine

196,070

1AE

Application fee for the purposes of paragraph   23B(2)(b) of the Act for an application under section   23 of the Act for registration of a medicine that is provisionally registered to be included in the part of the Register for goods known as registered goods

33,903

1AF

Evaluation fee for the purposes of subsection   24(1A) of the Act for an application under section   23 of the Act for registration of a medicine that is provisionally registered to be included in the part of the Register for goods known as registered goods

142,955

1AG

Application fee for the purposes of paragraph   29(5)(d) of the Act for an application under subsection   29(4) of the Act

20,455

1B

Application fee for the purposes of paragraph   25AAA(3)(d) of the Act for therapeutic goods (priority applicant) determination in relation to a medicine

14,805

2

Application fee for the purposes of paragraph   23B(2)(b) of the Act for registration of therapeutic goods (if regulation   43A does not apply):

(ba) for an application relating to a medicine in relation to which an evaluation fee is payable under paragraph   (a) of item   4

56,844

(bb) for an application relating to a medicine in relation to which an evaluation fee is payable under subparagraph   (aa)(i) or (ii) of item   4

18,872

(bc) for an application relating to a medicine in relation to which an evaluation fee is payable under subparagraph   (aa)(iii) of item   4

37,857

(bca) for an application relating to a medicine in relation to which an evaluation fee is payable under paragraph   (ab) of item   4

60,234

(bcb) for an application relating to a medicine in relation to which an evaluation fee is payable under paragraph   (ac) of item   4

1,299

(bd) for an application relating to a medicine in relation to which an evaluation fee is payable under paragraph   (b) of item   4

33,903

(be) for an application relating to a medicine in relation to which an evaluation fee is payable under subparagraph   (bb)(i) or   (ii) of item   4 for an evaluation of:

(i) an extension of indications

11,267

(ii) a major variation

7,356

(bf) for an application relating to a medicine in relation to which an evaluation fee is payable under subparagraph   (bb)(iii) of item   4 for an evaluation of:

(i) an extension of indications

22,715

(ii) a major variation

14,692

(bfa) for an application relating to a medicine in relation to which an evaluation fee is payable under paragraph   (bd) of item   4

35,823

(bg) for an application relating to a medicine in relation to which an evaluation fee is payable under paragraph   (c) of item   4

21,923

(bh) for an application relating to a medicine in relation to which an evaluation fee is payable under paragraph   (d) of item   4

3,582

(bi) for an application relating to a medicine in relation to which an evaluation fee is payable under paragraph   (g) of item   4

22,150

(bj) for an application relating to a medicine in relation to which an evaluation fee is payable under paragraph   (h) of item   4

1,299

(bk) for an application relating to a medicine in relation to which an evaluation fee is payable under paragraph   (bc) of item   4

1,299

(c) subject to paragraph   (d), for an application in any other case

5,175

(d) if a person submits more than one application at the same time and:

(i) the additional application is in relation to goods that contain the same therapeutically active ingredient; and

(ii) the information in support of each application is sufficiently common in respect of the goods to enable a simultaneous evaluation of the goods to be made

2,577--for each additional application, up to a maximum amount payable of 15,031 (including the fee payable under paragraph   (c))

2A

Fee for varying an entry in the Register (not including evaluation of data) under section   9D (other than subsection   9D(2C)) of the Act, if the variation is for:

(a) a registered medicine that is mentioned in Part   1 of Schedule   10--for each submission

1,989

(b) a listed medicine

496

(c) a disinfectant

1,466

(d) a Class 3 or Class 4 IVD medical device that is not covered by paragraph   (g)

1,832

(e) an IVD medical device that is not:

(i) a Class 3 or Class 4 IVD medical device; and

(ii) covered by paragraph   (g)

1,047

(f) a medical device that is not:

(i) an IVD medical device; and

(ii) covered by paragraph   (g)

1,047

(g) a medical device, if the following are satisfied:

(i) the reason for the variation is that the kind of medical device is affected by the EU transition (within the meaning of subregulation   9.1AA(3) of the Therapeutic Goods (Medical Devices) Regulations   2002 );

(ii) the variation only relates to an update to the manufacturer's evidence for the medical device recorded in the entry in the Register for that kind of medical device;

(iii) the request is to vary one or more entries in the Register and the manufacturer's evidence to which the update relates is the same for each of the entries

199 per 10 entries (or part thereof)

2AC

Application fee for an application under subsection   9D(3) of the Act to which regulation   16D applies

1,299

2B

Evaluation fee in relation to an application under subsection   9D(3) of the Act to which regulation   16F applies, for the evaluation of data--for each submission

6,486

2C

Evaluation fee in relation to an application under subsection   9D(3) of the Act to which regulation   16D applies, for the evaluation of data--for each submission

5,187

2CA

Evaluation fee in relation to an application under subsection   9D(2) of the Act, for the evaluation of data--for each submission

6,486

2CB

Fee for a request under subsection   9D(2C) of the Act (other than a request to which item   2CC, 2CD or 2CE applies) to make one or more variations of one or more entries in the Register in relation to a medicine:

(a) for each entry, unless paragraph   (b) applies

950

(b) in the case of a single entry in the Register, if the request is made together with a request of a kind mentioned in item   5 of Part   3 in relation to the same entry

Nil

2CC

Fee for a request under subsection   9D(2C) of the Act to make the same variation or variations of 2 or more entries in the Register that each relate to a registered complementary medicine--for each group of up to 7 entries

950

2CD

Fee for a request under subsection   9D(2C) of the Act to make the same variation or variations of 2 or more entries in the Register that each relate to a registered OTC medicine:

(a) for each group of up to 7 entries, unless paragraph   (b) applies

950

(b) for each group of up to 20 entries, if the request is made together with a request of a kind mentioned in item   5 of Part   3, in relation to the same group of entries

Nil

2CE

Fee for a request under subsection   9D(2C) of the Act to make the same variation or variations of 2 or more entries in the Register if:

(a) each entry relates to a prescription medicine or a biological medicine; and

(b) 2 or more of those medicines have the same active ingredient

The sum of:

(a) for each group of entries relating to medicines with the same active ingredient--950; and

(b) for any other entry--950

3

Application fee for paragraph   23C(2)(c) of the Act for the listing of therapeutic goods (other than for an application to which regulation   43A applies) if the goods are:

(a) a disinfectant

2,303

(b) a medicine

983

3AB

Fee for a notice and declaration under subregulation   43AAE(2) relating to an exemption from liability to pay an annual registration charge, annual listing charge or annual charge for inclusion in the Register in respect of therapeutic goods for a financial year:

(a) if the notice and declaration relate to not more than 5 entries in the Register

496

(b) if the notice and declaration relate to 6 or more entries in the Register

496 for the first 5 entries plus 57 for each additional entry

4

Evaluation fee, for subsection   24(1A) of the Act, under a submission for evaluation relating to:

(a) a new chemical entity (other than an entity to which paragraph   (aa), (ab) or (ac) of this item, paragraph   (a) of item   1AD or item   1AF applies)

227,825

(aa) a new chemical entity incorporated as an ancillary medicinal component of a medical device if the evaluation of the new chemical entity involves an evaluation of:

(i) documentation setting out the chemistry, quality control and manufacturing of the new chemical entity; or

76,055

(ii) documentation relating to pre - clinical studies; or

76,055

(iii) documentation mentioned in subparagraphs   (i) and (ii)

151,545

(ab) a new prescription medicine in relation to which a therapeutic goods (priority applicant) determination is in force

240,934

(ac) a vaccine for COVID - 19, respiratory syncytial virus (RSV) or influenza that is a new chemical entity, if:

(i) the vaccine is a new chemical entity only because the vaccine is for a new strain; and

(ii) the vaccine is a closely related form of an existing vaccine, for another strain, in the Register in relation to which the applicant is the sponsor

5,187

(b) an extension of indications (other than an extension of indications to which paragraph   (bb), (bc) or (bd) of this item, paragraph   (b) of item   1AD or item   1AF applies)

135,158

(bb) an extension of indications or a major variation in respect of a medicine incorporated as an ancillary medicinal component of a medical device if the evaluation of the medicine involves an evaluation of:

(i) documentation setting out the chemistry, quality control and manufacturing of the medicine; or

for an evaluation relating to:

(a) an extension of indications--45,090

(b) a major variation--29,269

(ii) documentation relating to pre - clinical studies; or

for an evaluation relating to:

(a) an extension of indications--45,090

(b) a major variation--29,269

(iii) documentation mentioned in subparagraphs   (i) and (ii)

for an evaluation relating to:

(a) an extension of indications--90,067

(b) a major variation--58,878

(bc) an extension of indications that is the subject of an application to which regulation   16G applies

5,187

(bd) a new indications medicine in relation to which a therapeutic goods (priority applicant) determination is in force

143,295

(c) a new generic product

87,016

(d) an additional trade name

14,239

(g) a major variation (that is not a variation mentioned in any of paragraphs   (a) to (d))

88,146

(h) a minor variation (that is not a variation mentioned in any of paragraphs   (a) to (d))

5,187

6AA

Fee for processing of data in relation to goods, a step in the manufacture of which was carried out outside Australia (in addition to any other fee prescribed in this Schedule in relation to the application) to determine whether the manufacturing and quality control procedures used in the manufacture of the goods are acceptable:

(a) for the purposes of subsection   9D(1), (2) or (3) of the Act; or

(b) for the purposes of paragraph   25(1)(g), 26(1)(g), 31(1)(e) or 31(2)(d) of the Act

757

6AB

Fee for Department obtaining evidence from overseas regulatory authority of the manufacturing and quality control procedures used in the manufacture of goods, a step in the manufacture of which was carried out outside Australia (in addition to fee prescribed in item   6AA)

814

6ABA

Fee for desk audit of overseas compliance certification to identify third party certifications and review the overseas compliance certification by examining the underlying audit report and obtaining information from the overseas regulators

2,894

6AC

Fee for reinstatement of acceptance status of data relating to the manufacturing and quality control procedures used in the manufacture of goods, a step in the manufacture of which was carried out outside Australia (in addition to fee prescribed in items   6AA and 6ABA)

1,367

6B

Fee for evaluation of data, under subsection   9D(1), (2) or (3) of the Act, about an entry in the Register relating to disinfectants

4,350

6BA

Application fee for a request, under subsection   30A(1) of the Act, for the revocation of the cancellation of the registration or listing of therapeutic goods from the Register:

(a) if the request relates to one registration or listing;

181

(b) if the request relates to more than one registration or listing

181 for the first registration or listing plus 57 for each additional registration or listing

6BB

Application fee for a request, under subsection   30AA(1) of the Act, for the revocation of the cancellation of the registration or listing of therapeutic goods:

(a) if the request relates to one registration or listing;

181

(b) if the request relates to more than one registration or listing

181 for the first registration or listing plus 57 for each additional registration or listing

6C

Fee for evaluating documents and other information, relating to the safety of a medicine, obtained under paragraph   31(2)(f) of the Act (other than an evaluation to which item   6D applies)

9,447

6D

Fee for evaluating documents and other information, relating to the safety, quality and efficacy of a medicine, obtained under paragraphs   31(2)(f) and (h) of the Act, if the total number of pages of the evaluation documentation is:

(a) not over 50 pages

12,431

(b) over 50 pages, but not over 250   pages

16,047

(c) over 250 pages, but not over 500   pages

21,923

(d) over 500 pages, but not over 1   000   pages

29,043

(e) over 1   000 pages, but not over 2   000   pages

43,508

(f) over 2   000 pages, but not over 3   000   pages

57,973

(g) over 3   000 pages

87,016

7A

Fee for evaluation under paragraph   16GA(1)(a):

(a) if the evaluation documentation does not contain clinical or toxicological information

(b) if the evaluation documentation contains clinical or toxicological information, and the total number of pages is:

12,431

(i) not over 50 pages

12,431

(ii) over 50 pages, but not over 250 pages

16,047

(iii) over 250 pages, but not over 500 pages

21,923

(iv) over 500 pages, but not over 1   000 pages

29,043

(v) over 1   000 pages, but not over 2   000 pages

43,508

(vi) over 2   000 pages, but not over 3   000 pages

57,973

(vii) over 3   000 pages

87,016

7B

Fee for evaluation, under paragraph   16GA(1)(b), in relation to 1 or more new excipients for use in particular therapeutic goods:

(a) if the evaluation documentation does not contain clinical or toxicological information

(b) if the evaluation documentation contains clinical or toxicological information, and the total number of pages is:

12,431

(i) not over 50 pages

12,431

(ii) over 50 pages, but not over 250   pages

16,047

(iii) over 250 pages, but not over 500 pages

21,923

(iv) over 500 pages, but not over 1   000 pages

29,043

(v) over 1   000 pages, but not over 2   000 pages

43,508

(vi) over 2   000 pages, but not over 3   000 pages

57,973

(vii) over 3   000 pages

87,016

7C

Application fee for the purposes of paragraph   26BJ(2)(d) of the Act

1,231

8

(a) Application fee for the purposes of paragraph   37(1)(g) of the Act, for a licence for:

927

(i) the manufacture of therapeutic goods; or

(ii) one or more steps in the manufacture of therapeutic goods; or

(iii) the manufacture of ingredients or components for use in the manufacture of therapeutic goods; or

(iv) the manufacture of herbal or homoeopathic preparations;

unless paragraph   (b) applies

(b) Application fee for the purposes of paragraph   37(1)(g) of the Act, for a licence for:

1,209

(i) the manufacture of haematopoietic progenitor cells; or

(ii) the manufacture of human blood and blood components (other than haematopoietic progenitor cells)

8A

Application fee for the purposes of paragraph   40B(2)(g) of the Act, for an application under subsection   40B(1) of the Act (addition of manufacturing sites) for the variation of a licence to which paragraph   (a) of item   8 applies

927

8B

Application fee for the purposes of paragraph   40B(7)(d) of the Act, for an application under subsection   40B(6) of the Act for the variation of the manufacturing site authorisation in relation to a licence to which paragraph   (a) of item   8 applies

927

8C

Application fee for the purposes of paragraph   40B(9B)(c) of the Act, for an application under subsection   40B(9A) of the Act (removal of manufacturing sites) for the variation of a licence to which paragraph   (a) of item   8 applies

927

9

(a) Fee for paragraphs 38(1)(c) and 58(3)(b) of the Act for inspection within Australia (except for therapeutic goods mentioned in items   9AA, 9AB, 9AC and 9ACA), per hour, per inspector, for:

1,153

(i) the manufacture of therapeutic goods; or

(ii) one or more steps in the manufacture of therapeutic goods; or

(iii) the manufacture of ingredients or components for use in the manufacture of therapeutic goods; or

(iv) the manufacture of herbal or homoeopathic preparations

(b) Fee for inspection outside Australia, per hour, per inspector, for inspection of a kind mentioned in paragraph   (a)

1,616

9AA

Fee for inspection (including an inspection for paragraph   58(3)(b) of the Act) of manufacturing premises or operations for the preparation of haematopoietic progenitor cells under licence, for each inspector engaged per hour, or part of an hour

790

9AB

Fee for inspection (including an inspection for paragraph   58(3)(b) of the Act) of manufacturing premises or operations for the preparation of human blood and blood components (other than haematopoietic progenitor cells) under licence, at the primary site covered by the licence, for each inspector engaged per hour, or part of an hour

1,074

9AC

Fee for inspection (including an inspection for paragraph   58(3)(b) of the Act) of manufacturing premises or operations for the preparation of human blood and blood components (other than haematopoietic progenitor cells) under licence, at a site covered by the licence (other than a site to which item   9AB applies), for each inspector engaged per hour, or part of an hour

790

9ACA

Fee for inspection (including an inspection for paragraph   58(3)(b) of the Act) of manufacturing premises or operations for the preparation of human tissues under licence, for each inspector engaged per hour, or part of an hour

790

9AD

Fee for paragraph   25(1)(g) or (h), or 26(1)(g) or (h) of the Act (and, in relation to associated inspections, for paragraphs   38(1)(c), 41(1)(f) and   58(3)(b) of the Act), in respect of the evaluation of the manufacture of human blood and blood components prepared under licence by reference to data contained in files known as technical master files or plasma master files, where the total number of pages of each file referred to is:

(a) not over 10 pages

1,560

(b) over 10 pages, but not over 50 pages

13,222

(c) over 50 pages, but not over 100 pages

29,833

(d) over 100 pages, but not over 1   000 pages

40,118

(e) over 1   000 pages, but not over 3   000 pages

62,493

(f) over 3   000 pages, but not over 4   000 pages

83,287

(g) over 4   000 pages

101,594

9D

Fee for evaluation, under subsection   9D(1), (2) or (3), subsection   24(1A) or paragraph   26(1)(d) of the Act, of data relating to the device component, to which Chapter   4 of the Act applies, of a medicine (in addition to the fee prescribed in item   4, or in Part   3 of this Schedule, for evaluating the medicine)

The fee applicable, under item   1.9, 1.10, 1.12 or 1.16 (and, if applicable, clause   2.2) of Schedule   5 to the Therapeutic Goods (Medical Devices) Regulations   2002 , to the kind of work to be undertaken

10

Fee for an application for certification under paragraph   58(3)(a) of the Act

204 multiplied by the number of certifications sought in the application

11

Fee for the inspection of manufacturing operations other than for the purposes of Part   3 - 3 of the Act

The fee applicable under item   9 for that step of manufacture

12

Fee for evaluation of data in relation to therapeutic goods specified in Schedule   10 for the purposes of subsection   9D(1), (2) or (3) of the Act that is not covered by another item in this Part

The fee applicable under item   1, 4 or 5 for an evaluation of that nature

13

Fee for an evaluation under subsection   66(4) of the Act

The fee applicable under item   1, 4 or 5 for an evaluation of that nature

14

Fee for notification required under item   3 of Schedule   5A:

(a) of intention to sponsor a clinical trial at a trial site using a specified medicine

429

(b) for each notification of an additional trial site or additional trial sites

429

16

Fee, including deposit, for an application under subsection   61(6) of the Act

The amount, including a deposit, that would be payable under the Freedom of Information Act 1982 and the Freedom of Information (Fees and Charges) Regulations for a request if the application were a request under section   15 of that Act

18

Fee for providing advice in relation to a prescription medicine at the request of the sponsor of the medicine for the purpose of listing the medicine as a pharmaceutical benefit

2,622

1

Application fee under paragraph   23B(2)(b) of the Act:

(a) for an N1 application

1,921

(b) for an N2 application

1,921

(c) for an N3 application

3,086

(d) for an N4 application

4,509

(e) for an N5 application

6,679

(f) for a C1 (section   23) application

1,921

(g) for a C2 (section   23) application

1,921

(h) for a C3 (section   23) application

1,921

(i) for a C4 (section   23) application

3,086

2

Evaluation fee under subsection   24(1A) of the Act:

(a) for an N1 application

4,746

(b) for an N2 application

6,747

(c) for an N3 application

10,397

(d) for an N4 application

17,290

(e) for an N5 application

25,426

(f) for a C2 (section   23) application

4,746

(g) for a C3 (section   23) application

7,967

(h) for a C4 (section   23) application

10,397

3

If, at the time a person submits an application of a kind mentioned in paragraph   (a), (b), (c), (d) or (e) of item   1:

(a) the person also submits an additional application or applications of the same kind; and

(b) each application relates to goods that contain the same therapeutically active ingredient; and

(c) the information in support of each application is sufficiently common in respect of the goods to enable a simultaneous assessment of the goods to be made;

the application fee under paragraph   23B(2)(b) of the Act for each additional application is:

(d) for an additional N1 application

972

(e) for an additional N2 application

972

(f) for an additional N3 application

1,549

(g) for an additional N4 application

1,549

(h) for an additional N5 application

1,549

4

If, at the time a person submits an application of a kind mentioned in paragraph   (c), (d) or (e) of item   2:

(a) the person also submits an additional application or applications of the same kind; and

(b) each application relates to goods that contain the same therapeutically active ingredient; and

(c) the information in support of each application is sufficiently common in respect of the goods to enable a simultaneous evaluation of the goods to be made;

the evaluation fee under subsection   24(1A) of the Act for each additional application is:

(d) for an additional N3 application

5,266

(e) for an additional N4 application

5,266

(f) for an additional N5 application

5,266

5

Application fee under paragraph   9D(7)(f) of the Act, for any of the following requests in relation to up to 20 entries in the Register:

(a) a C1 (section   9D) application

1,921

(b) a C2 (section   9D) application

6,679

(c) a C3 (section   9D) application

9,899

(d) a C4 (section   9D) application

13,448

7

Fee for providing advice in relation to a registered OTC medicine at the request of the sponsor of the medicine for the purpose of listing the medicine as a pharmaceutical benefit:

(a) if the request does not contain clinical data

1,887

(b) if the request contains clinical data or a justification as to why such data is not needed

9,674

1A

Application fee under paragraph   9D(7)(f) of the Act for an L(A)C1 (section   9D) request

2,316

1B

Application fee under paragraph   9D(7)(f) of the Act for an L(A)C2 (section   9D) request

10,115

1C

Application fee under paragraph   9D(7)(f) of the Act for an L(A)CN (section   9D) request

927

1D

Application fee under paragraph   23B(2)(b) of the Act for an L(A)C1 (section   23) application

1,074

1E

Application fee under paragraph   23B(2)(b) of the Act for an L(A)C2 (section   23) application

1,074

1F

Application fee under paragraph   23B(2)(b) of the Act for an L(A)CN (section   23) application

927

1G

Evaluation fee under subsection   26AC(2) of the Act for an L(A)C1 (section   23) application

1,244

1H

Evaluation fee under subsection   26AC(2) of the Act for an L(A)C2 (section   23) application

9,041

1

Application fee under paragraph   9D(7)(f) of the Act for an RCMC1 (section   9D) request

1,685

2

Application fee under paragraph   9D(7)(f) of the Act for an RCMC2 (section   9D) request

5,684

3

Application fee under paragraph   9D(7)(f) of the Act for an RCMC3 (section   9D) request

8,442

4

Application fee under paragraph   9D(7)(f) of the Act for an RCMC4 (section   9D) request

11,980

5

Application fee under paragraph   23B(2)(b) of the Act for an RCMC1 (section   23) application

1,685

6

Application fee under paragraph   23B(2)(b) of the Act for an RCMC2 (section   23) application

882

7

Evaluation fee under subsection   24(1A) of the Act for an RCMC2 (section   23) application

4,791

8

Application fee under paragraph   23B(2)(b) of the Act for an RCMC3 (section   23) application

950

9

Evaluation fee under subsection   24(1A) of the Act for an RCMC3 (section   23) application

7,504

10

Application fee under paragraph   23B(2)(b) of the Act for an RCMC4 (section   23) application

972

11

Evaluation fee under subsection   24(1A) of the Act for an RCMC4 (section   23) application

11,086

12

Application fee under paragraph   23B(2)(b) of the Act for an RCM1 application

644

13

Evaluation fee under subsection   24(1A) of the Act for a RCM1 application

3,695

14

Application fee under paragraph   23B(2)(b) of the Act for an RCM2 application

2,316

15

Evaluation fee under subsection   24(1A) of the Act for a RCM2 application

24,748

16

Application fee under paragraph   23B(2)(b) of the Act for an RCM3 application

2,316

17

Evaluation fee under subsection   24(1A) of the Act for a RCM3 application

24,748

18

Application fee under paragraph   23B(2)(b) of the Act for an RCM4 application

3,062

19

Evaluation fee under subsection   24(1A) of the Act for a RCM4 application

33,677

20

Application fee under paragraph   23B(2)(b) of the Act for an RCM5 application

3,356

21

Evaluation fee under subsection   24(1A) of the Act for a RCM5 application

42,943

22

Application fee under paragraph   23B(2)(b) of the Act for an L(A)1 application

520

23

Evaluation fee under subsection   26AC(2) of the Act for an L(A)1 application

1,978

24

Application fee under paragraph   23B(2)(b) of the Act for an L(A)2 application

2,136

25

Evaluation fee under subsection   26AC(2) of the Act for an L(A)2 application

16,387

26

Application fee under paragraph   23B(2)(b) of the Act for an L(A)3 application

2,136

27

Evaluation fee under subsection   26AC(2) of the Act for an L(A)3 application

16,387

28

Application fee under paragraph   26BD(3)(c) of the Act for an IN1 application

1,266

29

Evaluation fee under paragraph   26BE(3)(b) of the Act for an IN1 application

17,065

30

Application fee under paragraph   26BD(3)(c) of the Act for an IN2 application

1,266

31

Evaluation fee under paragraph   26BE(3)(b) of the Act for an IN2 application

17,065

32

Application fee under paragraph   26BD(3)(c) of the Act for an IN3 application

3,356

33

Evaluation fee under paragraph   26BE(3)(b) of the Act for an IN3 application

27,800

34

Application fee under paragraph   26BD(3)(c) of the Act for an IN4 application

3,356

35

Evaluation fee under paragraph   26BE(3)(b) of the Act for an IN4 application

27,800